830 related articles for article (PubMed ID: 26405702)
1. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.
Yao J; Zuo L; An G; Yue Z; Zhao H; Wang L; Liu F
J Gastrointestin Liver Dis; 2015 Sep; 24(3):301-7. PubMed ID: 26405702
[TBL] [Abstract][Full Text] [Related]
2. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
[TBL] [Abstract][Full Text] [Related]
3. Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy.
Deng D; Liao MS; Qin JP; Li XA
Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):232-6. PubMed ID: 16698582
[TBL] [Abstract][Full Text] [Related]
4. Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension.
Wei J; Li H; Li C
J Cancer Res Ther; 2018; 14(4):826-832. PubMed ID: 29970660
[TBL] [Abstract][Full Text] [Related]
5. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.
Luo SH; Chu JG; Huang H; Zhao GR; Yao KC
World J Gastroenterol; 2019 Mar; 25(9):1088-1099. PubMed ID: 30862997
[TBL] [Abstract][Full Text] [Related]
6. Observational cohort study of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS).
Routhu M; Safka V; Routhu SK; Fejfar T; Jirkovsky V; Krajina A; Cermakova E; Hosak L; Hulek P
Ann Hepatol; 2017; 16(1):140-148. PubMed ID: 28051803
[TBL] [Abstract][Full Text] [Related]
7. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
[TBL] [Abstract][Full Text] [Related]
8. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P
Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458
[TBL] [Abstract][Full Text] [Related]
9. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
Colombato L
J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
[TBL] [Abstract][Full Text] [Related]
10. Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt.
Bai M; He CY; Qi XS; Yin ZX; Wang JH; Guo WG; Niu J; Xia JL; Zhang ZL; Larson AC; Wu KC; Fan DM; Han GH
World J Gastroenterol; 2014 Jan; 20(3):774-85. PubMed ID: 24574750
[TBL] [Abstract][Full Text] [Related]
11. Bayesian network-based survival prediction model for patients having undergone post-transjugular intrahepatic portosystemic shunt for portal hypertension.
Chen R; Luo L; Zhang YZ; Liu Z; Liu AL; Zhang YW
World J Gastroenterol; 2024 Apr; 30(13):1859-1870. PubMed ID: 38659484
[TBL] [Abstract][Full Text] [Related]
12. Parallel transjugular intrahepatic portosystemic shunt for controlling portal hypertension complications in cirrhotic patients.
He FL; Wang L; Yue ZD; Zhao HW; Liu FQ
World J Gastroenterol; 2014 Sep; 20(33):11835-9. PubMed ID: 25206289
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
Wang Z; Wu YF; Yue ZD; Zhao HW; Wang L; Fan ZH; Zhang Y; Liu FQ
World J Gastroenterol; 2021 Feb; 27(5):416-427. PubMed ID: 33584073
[TBL] [Abstract][Full Text] [Related]
14. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy.
Pereira K; Carrion AF; Martin P; Vaheesan K; Salsamendi J; Doshi M; Yrizarry JM
Liver Int; 2015 Dec; 35(12):2487-94. PubMed ID: 26332169
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt.
Lu HL; Xuan FF; Luo YC; Qin X
Abdom Radiol (NY); 2021 Nov; 46(11):5417-5427. PubMed ID: 34302511
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of hepatic encephalopathy and portal hemodynamics by Doppler ultrasonography after a transjugular intrahepatic portosystemic shunt].
Kimura M; Sato M; Kawai N; Tanihata H; Horihata K; Shioyama Y; Sonomura T; Yoshikawa A; Kishi K; Terada M; Yamada R
Nihon Igaku Hoshasen Gakkai Zasshi; 1997 Apr; 57(5):233-7. PubMed ID: 9164110
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts.
Tesdal IK; Wikström M; Flechtenmacher C; Filser T; Dueber C
Cardiovasc Intervent Radiol; 2006; 29(5):778-84. PubMed ID: 16779690
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
Teng D; Zuo H; Liu L; Dong J; Ding L
Virol J; 2018 Oct; 15(1):151. PubMed ID: 30285813
[TBL] [Abstract][Full Text] [Related]
19. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications?
Chung HH; Razavi MK; Sze DY; Frisoli JK; Kee ST; Dake MD; Hellinger JC; Kang BC
J Gastroenterol Hepatol; 2008 Jan; 23(1):95-101. PubMed ID: 18171347
[TBL] [Abstract][Full Text] [Related]
20. A novel endovascular adjustable polytetrafluoroethylene-covered stent for the management of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
Weintraub JL; Mobley DG; Weiss ME; Swanson E; Kothary N
J Vasc Interv Radiol; 2007 Apr; 18(4):563-6. PubMed ID: 17446548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
